CELLTRION GROUP UNVEILS RESULTS FOR COCKTAIL THERAPY CANDIDATES
KUALA LUMPUR, Jan 4 (Bernama) -- Celltrion Group has announced results for its cocktail therapy candidates including neutralisation data against the Omicron variant (B.1.1.529).
The Phase I clinical trial is a randomised, double-blind and placebo-controlled trial designed to evaluate the safety, tolerability and pharmacokinetics of CT-P63 in 24 healthy subjects in Poland.
“The positive results demonstrate the potential of our cocktail therapy to retain neutralising ability against the Omicron variant,” said Head of Medical and Marketing Division at Celltrion Healthcare, Dr HoUng Kim, Ph.D.
“We are confident that our antibody platform including Regkirona and CT-P63 will provide significant benefit for patients with COVID-19.”
According to a statement, the study met its primary objectives with data showing CT-P63 to be safe and well tolerated, with no significant drug-related adverse events (AEs).
In an experiment conducted in partnership with the National Institutes of Health (NIH), CT-P63 showed strong neutralising activity against the Omicron variant based on structural analysis by X- ray crystallography and neutralisation data from pseudo-virus testing.
Celltrion anticipates results of the SARS-CoV-2 Omicron variant assays and animal model studies by the end of the first quarter this year.
In order to elicit potent neutralising antibody response against the new emerging variants, Celltrion previously identified 38 potent neutralising antibodies against SARS-CoV-2 in which antibody candidate No. 32 (CT-P63) produced high neutralisation titres against new emerging strains.
More details at https://www.celltrionhealthcare.com/en-us.
-- BERNAMA
Comments